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This thesis explores the possibility of detecting early signs of potentially life 
threatening melanoma through a simple blood test before the cancer reaches an 
untreatably fatal stage. There is promising data to support that such an assay is possible 
to determine whether a patient may have metastatic melanoma. This early detection is 
possible because the body appears to synthesize antibodies against transient receptor 
potential melastatin 1 (TRPM1), when under the stress of metastatic melanoma. We can 
easily synthesize the portion of TRPM1 peptide that the human antibody recognizes, 
and therefore measure whether or not the patient has these critical antibodies in their 
blood serum. The presence of these antibodies is a red flag and can hopefully lead to 
immediate examination from a doctor who may be able to stop the disease from 
progressing further. This assay can hopefully save many lives.   
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Chapter 1: Introduction  
Significance of Research 
Cancer has plagued mankind since our inception (Bianconi et al. 2013). Cells 
are constantly being replaced with new ones, albeit at different rates for different cell 
types. While this process keeps the human body functioning, billions upon billions of 
mitosis stages can take their toll on a cell (Milo and Phillips, 2016). Even though the 
cell has many safeguards against errors while replicating itself, mistakes do happen in 
rare instances. These mistakes lead to mutations in the genome. While mistakes are not 
always malignant, they sometimes can cause harm. Mistakes often lead to 
predispositions to real damage. This damage comes in the form of cancers, cells that no 
longer have safeguards on them. Cancerous cells can arise from many different 
mutations, but generally replicate with impunity, will not willingly undergo apoptosis, 
and will crowd out neighboring cells. In 2010, one in four deaths in the United States 
was caused by cancer (Jemal et al. 2010). My research aims to help at least one subset 
of those patients get help before it is too late.  
Statement of Purpose 
As one of the fastest growing and most malignant skin cancer, my research 
endeavors to find an effective, inexpensive, and easy way to screen patients for 
metastatic melanoma (Bello, 2013). In metastatic melanoma, malignant melanocytes 
migrate to other parts of the body, potentially spreading the cancer to critical and life 
sustaining organs (Lu, 2009). Screening patients for this cancer requires a reliable 
biomarker that sets the metastatic melanoma patients apart from healthy counterparts. 
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One such potential biomarker is a protein, transient receptor potential melastatin 1 
(TRPM1), that is normally only found in melanocytes and ON-bipolar cells in the retina 
(Xiong et al. 2013). The body’s immune system then produces autoantibodies against 
TRPM1, presumably because it is out of place.   
Research Question 
Does screening for presence of TRPM1 autoantibodies diagnose early stages of 
metastatic melanoma so that the patient can be diagnosed, treated, and helped in a 
timely manner?  
Hypothesis 
I hypothesize that this research will apply to all metastatic melanoma patients, in 
that all patients start creating these autoantibodies after their melanocytes start 
replicating out of control and spreading.
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Chapter 2: Background 
Cancer 
 
Figure 1: The cell cycle 
Most cell types undergo mitosis, during which they replicate everything within them 
and divide into two cells. A new cell undergoes a primary growth stage (G1), at which 
point there is a checkpoint to make sure that the external requirements for growth have 
been met. After this, the cell replicates its DNA. A second growth stage follows (G2), 
and then another checkpoint ensues, to make sure that all of the chromosomes are 
duplicated correctly. Once the cell has detected that everything is in order, it pinches 
itself into two, and generates two independent cells, ready to either repeat the process, 
or remain undivided.  
Mutations can occur that disrupt the checkpoints in critical ways. Certain 
proteins are necessary to carry out those checkpoints, and if they have lost their 
function, then the cell may proceed with replication without making sure that the DNA 
is perfectly replicated as it should be. Once DNA is replicated erroneously, it becomes 
New Cell New Cell 
Proper Chromosome duplication 
assessed 
Integri ty of DNA is checked 
Problems arise with mutations: 
Tumor suppressor and 
Proto-oncogenes 
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much easier for more mutations to occur in the genome. The host is in danger when 
these mutations eventually lead towards rapid cell proliferation and become cancerous.  
Not all cells in the human body undergo many rounds of mitosis throughout a 
lifetime. Certain organs within a human body, however, proliferate throughout 
adulthood. The skin, the body’s largest organ, constantly needs to regenerate in order to 
perform its many functions. Melanocytes are just one of the several cell types within the 
skin organ. 
Generating Antibodies and Autoantibodies 
The human immune system works by recognizing harmful intruders, marking 
them as dangerous, and then eliminating them from the system or blocking their 
function. One facet of that defensive system involves white blood cells called B-cells 
carrying antibodies on their surface. There are millions of unique B-cells in our blood, 
each coated with their own distinctive antibodies, primed to recognize a specific target. 
Antibody targets are called antigens. The body creates a huge amount of B-cells with 
randomized antibodies with the hope that it can recognize any conceivable threat. 
Antibodies that would recognize the self as a target are degraded (Berg 2002). 
When the antibody on a B-cell happens to find its pairing with an antigen while 
it is circulating in the blood, it becomes activated. The B-cell begins replicating itself 
and producing a large amount of its unique antibodies. Some B-cells will migrate to the 
spleen and will wait on hold until they are needed again. The rest will release their huge 
stores of antibodies into the blood. These antibodies will then be able to circulate, bind, 
and assist in the degradation or inactivation of whatever antigen had originally activated 
the original B-cell. This process is why the body is so effective at fighting off a repeat 
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exposure to infection or disease. For example, people generally do not get chicken pox 
twice.  
There is much mystery surrounding the immune system attacking its own cells, 
a process known as autoimmunity. For example, type I diabetics have had their beta 
cells within their pancreas destroyed, and are no longer able to produce insulin. The 
beginnings of this mechanism are unknown, though there are several theories on how 
cancer can spark autoimmune events. These include tolerance defects, inflammation, 
altered protein structure, cellular death mechanisms, and changes in expression levels 
(Zaenker et al. 2016).  
In my research, I consider how cancerous melanocytes could lead to an instance 
of autoimmunity, although it is possible that there are simultaneous factors at play. A 
tolerance defect refers to the body’s possible inability to delete B-cells that would 
recognize itself as a target. This defect remains less likely, because the body attains this 
autoimmunity spontaneously without a metastasizing cancer to induce it. Inflammation 
is a viable cause of autoimmunity, because as the melanocytes are growing out of 
control, it creates local sites of swelling corresponding to the proliferation of cells. This 
growth increases the permeability to the nearby vasculature, which would provide easier 
access for circulating B-cells to recognize an antigen and become active, beginning the 
cascade of events previously described as an immune response. Altered protein 
structure is a possible cause of autoimmunity, but not probable. If the same protein 
associated with melanocytes were mutated in such a way that it was recognized by a B-
cell, then it does not make sense that the released antibodies would be able to recognize 
local, unaltered version of protein and become an autoimmune issue.   
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Another possibility of how autoimmunity develops is the way in which the body 
is fighting the cancer. Cells normally die through apoptosis, which is a generally a swift 
and clean way to eliminate a cell that is supposed to die. In killing cancer cells, the 
process becomes erratic and stochastic, and cell contents can spew out into places like 
the blood stream. Proteins that are not normally in the blood stream could then be 
recognized as an antigen, and be targeted by the immune system. 
Finally, and similar to inflammation, altered expression levels could be the 
cause of autoimmune responses. With metastasizing cells, they are growing where they 
do not belong, and also at much higher levels than normal. This higher expression level 
could then be the tipping point that triggers an immune response. Metastasizing cancer 
cells have thousands of protein associations that could become targets for B-cells. 
Antibodies could be recognizing mutated proteins associated with the melanocytes, 
other over-expressed proteins, or other proteins that are simply out of place.  
Transient Receptor Potential cation channel Subfamily M member 1 
The name of the protein gives some clues to its function: transient refers to the 
fact that it is a protein that spans the distance between the inside and outside of a cell. It 
is a receptor because it is able to receive a signal and act accordingly. Upon activation it 
undergoes a conformational change and allows for the passage of calcium and sodium 
from the outside of the cell to the inside, acting as a channel. Calcium is a basic but 
crucially important element, because it is capable of doing so much in the cell, 
depending on the conditions of entry. Sodium is an important positively charged ion 
that will help to depolarize the cell. For the TRPM1 channels in the retina, the calcium 
will help propagate a certain visual pathway that takes place in low-light conditions, and 
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the signal will eventually form an image in the brain (Morgans et al. 2010). The 
function of the TRPM1 channel in the melanocytes is less understood, but it is believed 
to help the body produce melanin, which is the molecule that helps pigment the skin 
(Devi et al. 2013).   
Melanoma Associated Retinopathy 
Some melanoma patients develop night blindness. The problem has been coined: 
Melanoma Associated Retinopathy (MAR). Research has shown that this arises from 
autoantibodies crossing the blood-retina barrier and entering the retina. The cause of the 
night blindness can be localized to the ON-bipolar cells in the retina. It is hypothesized 
that at a certain point in the onset of melanoma, the body builds up autoantibodies 
against certain antigens relating to the cancer. One such antigen would be TRPM1, 
which is found in melanocytes and in the retina (Devi et al. 2013). The body’s immune 
system must have recognized the TRPM1 channel where it was not supposed to be, and 
sent out an immune response against it (Maio, 2012). The TRPM1 autoantibodies found 
their way into the retina while traveling through the blood, and end up binding to the 
TRPM1 channel in retinal bipolar cells. By obstructing this channel in the bipolar cells, 
the depolarization that is necessary for the brain to interpret an image in low-light 
conditions is inhibited, and the patient is affected by night blindness. 
Current Screening Methods for Melanoma 
The current state of screening for melanoma is not very effective. At this point, 
doctors usually give a total-body skin examination to patients who are extremely at risk, 
or else they simply rely on a patient’s initiative to get something checked out (Erika et 
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al. 2005). One must distinguish benign pigmented lesions from early melanoma. 
Looking out for asymmetry, border, color, diameter, and the elevation of the lesion is 
critical when trying to identify early melanoma. Essentially, if it is not symmetrical, 
flat, brown, or flush with the rest of your skin, you have reason for concern. Usually in 
order to diagnose the problem, the doctor would extract the lesion and wait for biopsy 
results. New experimental non-invasive procedures may be just as effective in 
diagnosing melanoma (Rigel et al. 2010). According to Rigel, the main issue in the 
process of helping people with melanoma is a lack of general expertise in recognizing 
melanoma. Health care professionals and common citizens alike are usually ill equipped 
to recognize what the danger signs are. An individual may be hesitant to consult a 
doctor about a mole that may appear to be innocuous.   
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Chapter 3: Experimental Procedures 
Immunofluorescence  
Immunofluorescence is a key method in cell biology research. It is an elegant 
way of harnessing the power of the relationship between antigen and antibody. An 
antibody sticks onto a certain antigen that it specifically recognizes. Setting up this 
reaction requires a reasonable amount of antigen available to be bound. The primary 
reaction is the addition of a primary antibody, which recognizes the antigen in question. 
The secondary reaction is the addition of a secondary antibody, which is often grown in 
some model mammal, which recognizes any antibody from the organism that made the 
primary antibody. This secondary antibody is also fluorescently labeled, so that it will 
emit a certain wavelength of light after being illuminated with light of a different 
(shorter) wavelength. The final step is to look at it under a microscope that can 
simultaneously shine the excitation wavelength and observe the emitted wavelength.  
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Figure 2: Immunfluorescence 
http://www.slideshare.net/ali7070/immunofluorescence-39956337 
Transfection 
Transfection offers a second key process in cell biology research. This technique 
involves the introduction of DNA into a Eukaryotic cell using non-viral methods. To do 
this, I followed a prescribed procedure that will allow Human Embryonic Kidney 293 
(HEK 293) cells to uptake a DNA plasmid containing the coding sequence of a protein 
of interest, transcribe it, and then translate it into the desired protein construct.  
Epitope Verification 
The first part of my project with Dr. Catherine Morgans at OHSU was the 
identification of the epitope of TRPM1 that reacted with TRPM1 autoantibodies present 
t .ntiqen Primary m ac lion 
Secondary r,e.actio 
Microscopic ,0,x.amination 
Unlabeled 
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in serum samples from MAR patients. Research that she had previously performed had 
isolated the epitope between the n-terminus and the cytoplasmic domain (Xiong et al. 
2013)
 
Figure 3: TRPM1 Protein 
The graphic above shows the general structure of TRPM1 protein. The blue bar represents the 
cell membrane, the purple strand represents the stretch of peptide between its beginning and 
transmembrane portion, the blue elipses represent the stretch of protein that goes back and forth between 
the inside and outside of the cell, and the orange strand represents the section of protein between the 
transmembrane and the end of the protein. 
  
Figure 4: Epitope Narrowing 
This represents the utilization of transfection and immunofluorescence techniques to 
glean critical information.  
Dr. Catherine Morgans performed this experiment before I joined the lab. The 
top two squares of figure 4 illustrate when cells have been successfully transfected. 
        N  1628 inside 
outside 
 79 115
N-terminus C-terminus 
aa1-799 aa1159-1628 
MAR Serum 
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HEK cells were transfected with a plasmid containing a blueprint to construct a certain 
amino acid sequence and also connected with Green Fluorescent Protein (GFP). The 
green immunofluorescence shows that the cell’s transfection was successful. If GFP is 
present, we can assume that the rest of the peptide was successfully transfected. The red 
fluorescence was a measure of whether or not the primary antibody had bound and 
recognized the epitope within the amino acid chain. In the case of peptide 1–799, the 
antibodies in MAR serum were able to recognize it, and therefore provide 
immunofluorescence. When HEK cells were transfected with amino acids 1159–1628, 
antibodies in MAR serum were unable to recognize it, which led to no 
immunofluorescence. This difference suggests that somewhere between amino acids 1 
and 799 is a sequence of amino acids that the antibody targets, called the epitope. 
 
Figure 5: Further Differentiation 
Dr. Morgans performed some further experiments to locate the epitope involved slicing 
the protein in different lengths. 
The top line is another visual representation of the TRPM1 protein. M1 
corresponds to the N-terminal methionine, and C1622 corresponds to the C terminus. 
This relationship shows the process of narrowing down which piece of protein, if 
Ml OMiEH~R4Lrllmm:i;mcma------------ c ,622 +++ 
M1------------------- G799 {BamHI) 
M1------------- GSS0 {Apal) 
M1--- 1147 (EooAV) 
Vl 49 (Apall)------- V430 (Accl) 
Vl49 (Apall)--- 0263 {Psll) 
K264 (PstQ-------GSS0 (Apal) 
K284 (Pstl)--- V430 (Accl) 
L1159 (Afl ll)----------- C1622 
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expressed, would lead to attachment of antibodies against TRPM1. These different 
pieces of the TRPM1 sequence were sliced up using certain restriction enzymes, which 
cut the DNA in specific places, depending on the enzyme used. These known smaller 
pieces can then be used to further narrow down where the epitope lies.  
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Figure 6: Further Narrowing 
HEK 293 cells were transfected with plasmids encoding different regions of TRPM1 
within exons 5-10 fused to GFP. The first column of images shows the GFP 
fluorescence of the transfected cells (green).  The second column shows 
immunofluorescence obtained with serum from a MAR patient (red). The third column 
shows the merged images from the first and second columns. Areas with both red and 
green fluorescence appear yellow. The fourth column shows differential interference 
contrast (DIC) images of the cells, so that both transfected and untransfected cells can 
be seen.  
Building on Dr. Morgans work, I was able to experimentally replicate her 
results, using a new MAR patient serum to identify which exons were parts of the 
epitope. Exons are the sections of DNA that are kept after RNA processing and will 
eventually be translated into protein. The whole of a gene’s DNA is not expressed to 
GFP Serum Merge DIC 
Ex 5,,7 
Ex 7-8 
Ex 7•9 
Ex tM O 
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protein, because the cell trims out certain pieces that are unneeded. I expressed different 
exon combinations of TRPM1 in human embryonic kidney cells (HEK293) cells using 
transfection. Once I had cells producing these TRPM1 polypeptides, I could then probe 
them with the MAR patient sera that had previously been determined to contain TRPM1 
autoantibodies. I confirmed that this MAR patient’s serum targeted the same TRPM1 
epitope as another patient’s serum that the lab has previously characterized. Although I 
would ideally continue to test more MAR patient sera to make sure that the epitope 
across patients is totally conserved, time constraints made this portion of the project 
impossible in the present experiment. If this epitope is truly conserved, then it will be 
easy to synthesize peptides of the epitope and test it against patient sera to determine 
whether or not the patient is producing antibodies against it.    
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Assay Creation 
 
 
Figure 7: Slot Blot Assay 
http://www.bio-protocol.org/attached/image/20150416/20150416022928_1386.jpg 
Figure 7 represents the slot blot assay apparatus that I assembled. Each column 
had a different serum or different concentration of serum, but consistent throughout the 
column. Each row had a different concentration of TRPM1 peptide concentration, 
serially diluted down. Each slot was filled with about 200 μl of solution, which was then 
sucked down by a vacuum. The protein peptides stick to the nitrocellulose membrane. 
The slots narrowed to slits, which is where the captured proteins stayed.  
/ Sample template with attached sealing screws 
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Figure 8: Assay 
I separated the nitrocellulose membrane from the filter paper once it had bound my 
desired concentrations of peptide. I then cut the strips of the membrane into columns. 
These were submerged in blocking solution, which coated the rest of the membrane in a 
plethora of non-specific proteins. This coating was important so that all the antibodies 
in the serum that we are testing did not stick to the nitrocellulose and give false signals. 
After this blocking process, we probed it with diluted patient sera to act as primary 
antibodies and then probed it with secondary antibodies after another wash. We finally 
measured its fluorescence, which were quantified using specialized machines as signal 
intensity.  
I had to experimentally adjust the assay to find out what parameters are ideal for 
the blood test. The dilutions of serum started at 1:500, then went to 1:1000, and then to 
1:2000. Concentrations of the peptide along the y-axis started at 1ng/microliter, and 
were then halved from one well to another, in a serial dilution. I experimented with 
further dilutions of serum, without much success. I then tried altering the rinsing 
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procedure to determine whether it would be more advantageous to use Phosphate 
Buffered Saline (PBS) or Bovine Serum Albumin (BSA). PBS is almost analogous to 
using water as a rinse, and BSA is used as a blocking solution.  A blocking solution 
would be necessary to make sure that there is no unnecessary binding to the 
nitrocellulose that our synthesized peptide has stuck to. The use of a blocking solution 
before probing our strips of nitrocellulose before adding primary antibodies made it 
unnecessary to add BSA at the same time as we were adding TRPM1 peptide. To do so 
could prevent the desired peptide from binding in the first place. 
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Chapter 4: Results 
The results of my experiments are summarized in figures 9–11. I found that the 
blood test is able to differentiate between normal patients and those with metastatic 
melanoma. 
 
 
 
Figure 9: Final Slot Blot  
This image was an example of the final slot blot test that I ran. I used six different sera, 
as shown above. S51, 4409, S38, and 4397 were known negatives (i.e. sera from 
healthy subjects); CMM13 was a patient with metastatic melanoma, and 9134 was a 
patient with melanoma associated retinopathy. Merely looking at this blot, columns 
CMM13 and 9134 clearly stand out, but it is also useful to look at a graphical 
representation of the data. 
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1:500 dilutions of 
4409 9134 S38 4397 
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Figure 10: Graphical Representation of Slot Blot 
On the x-axis is the concentration of the TRPM1 peptide. The y-axis is the signal 
intensity. The different lines represent the different sera that I used. At concentrations 
higher than 2 ng/μl of TRPM1 peptide, the signal loses specificity, and there is little 
difference between the negative and positive sera. At concentrations lower than 0.25 
ng/μl, there is hardly enough peptide to elicit a signal from the sera at the dilution used 
(1:500). Between 0.25 ng/microliter and 2 ng/microliter TRPM1 polypeptide was the 
critical area that allowed discrimination between positive and negative sera. 
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Figure 11: Blow up of Important Information 
This graph demonstrates a stark contrast between the signal intensities from sera that 
had melanoma, and those that did not. Serum 9134 had metastatic melanoma and 
reported vision problems, and CMM13 had metastatic melanoma, but had no reported 
vision problems. The rest of the sera did not have any melanoma.  
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Chapter 5: Discussion 
I anticipate that this research may apply to all metastatic melanoma patients, in 
that all patients could be creating these autoantibodies after their melanocytes start 
replicating out of control. I have obtained promising results, but the only way to refute 
or build upon them is to perform more research. If I had access to more sera of people 
who do not have melanoma and also from patients who are at known stages of 
melanoma progression, I could get a much clearer idea of how viable my research is, on 
a clinical level. It is crucial to establish at what stage of the cancer the autoantibodies 
are being produced, or what percentage of patients even produce these autoantibodies.  
Connecting melanoma to certain autoantibodies arose from a rare instance. 
Problems with night blindness only occur in a subset of patients with metastatic 
melanoma when the blood-retinal barrier is compromised, allowing a small amount of 
leakage of the autoantibodies into the retina. It is very rare for someone to come in with 
issues of night blindness and have it lead to a diagnosis of melanoma, but it has 
happened before (Dalal et al. 2013). This technique may be able to help diagnose 
melanoma before situations get dire.  
It is my hope that this simple blood test will provide a patient with information 
about the risk of melanoma. A small blood sample is considerably less invasive than a 
full-body examination. If the blood sample comes back positive for the autoantibodies, 
then the patient and doctor can work together to nip the problem in the bud, before it 
gets considerably more life threatening or fatal.  
There are five main stages of categorizing melanoma, with many sub-stages in 
between. Stage 0 is just on the surface of the skin, and is easily surgically removed. 
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Stages I–II are still in the skin, have grown wider and deeper, yet can still be surgically 
removed without much worry about it spreading. It becomes more complicated in stage 
III, when the cancer has spread to a lymph node, which is usually responsible for 
cleaning out normal waste in the body. From there, it is generally easier for the cancer 
to spread to other organs of the body, and become classified as stage IV. When treating 
stage III or stage IV melanoma, it is more common to turn to radiation, immunotherapy, 
targeted therapy, or chemotherapy. The real danger of melanoma comes from the 
metastization of the cancer, spreading from the outer layer of the skin to inner layers, to 
the lymph nodes, and to organs that are necessary to sustain life.  
This detection of TRPM1 autoantibodies will have prognostic value to the 
patient. Hopefully, this method could catch the problem at stage III, where it is more 
easily treatable, before it goes to a more dangerous stage IV. It is also possible that the 
presence of antibodies against TRPM1 is an indication that the body is putting up a 
fight against the cancer, and that the patient has a high chance of survival.  
Immunotherapy is a burgeoning field in the fight against melanoma and cancer 
in general. The treatment essentially aims to help the body fight its own battle against 
the cancer by boosting the immune system, or helping the body recognize the cancer as 
something to be destroyed. It would be interesting to research how TRPM1 
autoantibodies could be incorporated into the therapeutic approach. Of course, there 
would always be the dangerous potential side effect that the antibodies would cross the 
blood brain barrier and interfere with the function of the TRPM1 protein in the retina.  
Moving forward, there is real promise in the further study of the role that 
TRPM1 autoantibodies play in patients with melanoma. Using my assay, it will be easy 
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to gain a greater understanding of how these antibodies are playing a role in patients at 
different stages of their cancer. With any luck, the autoantibodies will be at significant 
levels and can be detected before the cancer has had a chance to spread to critical 
organs, and lives can be saved. 
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Glossary 
Apoptosis: The process of controlled suicide that a cell undergoes if it is functioning, 
and has reached a point at which it should die.  
 
Amino acid: The building blocks of a protein. There are 21 unique ones. Each one has 
an amine group (NH2), a carboxyl group (COOH), and a side chain. These side chains 
are what make each amino acid unique. The first amino acid has a free amine group, 
and then a peptide bond forms between its carboxyl group and the next amino acid’s 
amine group. The amino acids daisy chain along to form a polypeptide.   
 
Antibody: A unit of immune response whose job is to tag certain sequences or cells. 
Different antibodies perform many different functions.  
 
Antigen: The sequence of amino acids that an antibody recognizes as a target. 
 
Assay: A biological test, where something is being tested. There is often a negative 
control, a positive control, and one to several experimental procedures.  
 
Autoantibody: A unit of immune response that recognizes some part of its own host as 
something that needs to be deactivated or destroyed.   
 
Blood brain barrier: A highly selective permeability barrier that separates the blood 
from the central nervous system (brain). Antibodies cannot usually get through, but may 
get through in small concentrations.   
 
Blood retinal barrier: Very similar to the blood brain barrier, except that this barrier is 
specifically at the choroid capillaries to retina connection.  
 
Capillary: A very small blood vessel that facilitates the exchange of nutrients, waste, 
and some other substances with the tissue surrounding it.  
 
Cancer: Mutations build up in the DNA, and cause problems to arise. Either proto-
oncogenes are affected, or tumor suppressor genes. These changes lead to rapid 
proliferation of cells, which will grow out of their usual spaces, eventually taking over 
other parts of the body. As the cancer spreads, it infects other cells, and normal 
functions start to fail.  
 
Channel protein: This is a protein that creates a specialized opening in a cell 
membrane that will let a certain molecule in or out, depending on current conditions 
inside or outside the cell. TRPM1 is a channel protein that is calcium permeable.  
 
Chromosomal DNA: The DNA that makes up the genome of an organism, and is 
conserved throughout all the organism’s cells. Chromosomes are huge strings of DNA, 
each containing hundreds of genes. Humans have twenty-three pairs of chromosomes.   
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Choroid: This is the vascular layer of the eye, providing oxygen and nourishment to the 
outer layers of the retina.  
 
C-Terminus: The last amino acid in a protein, as defined by its open carboxyl Group 
(COOH).  
 
Depolarization: refers to how a cell propagates a signal. Cells are normally held in a 
state of hyperpolarization, lower in voltage than the surrounding interstitial fluid. When 
cells intake positive ions, it is voltage potential increases, closer to that of the 
surrounding fluid, therefore depolarizing.  
 
Differential interface contrast: Microscopy technique to view contrast in in 
transparent samples. Good and common for visualizing cells.  
 
Dilute: To lessen the concentration of something, usually done by adding water to the 
solution.  
 
DNA: An essential part of biology. It is essentially the coding that dictates much of who 
a person is. A person’s genetic code refers to their whole sequence of DNA. Everyone 
has a unique genetic code. Even twins have very slight variations. 
 
Enzyme: Is a type of protein. They generally accept a substrate, undergo some shape 
change, release a product, and undergo another shape change so that it can perform the 
process again and again.  
 
Epitope: The sequence that an antibody recognizes and latches onto.  
 
Eukaryotic cells: Cells that have a nucleus and organelles encased in membranes.  
 
Genome: The biological information of heredity that is passed down from organism to 
organism. Each genome is unique, as it is the specific order of nucleotides making up 
the DNA of an organism. Genomes between siblings will look much more similar than 
genomes between distant strangers, and even more so if comparing across species. 
 
HEK293 cells: Human Embryonic kidney cells, are a specific cell line developed to 
grow in tissue culture. These cells are relatively easy to grow, and you can experiment 
on them effectively because they grow well and are transfectable.  
 
Interstitial fluid: The liquid that makes up the space in between cells.  
 
Metastasis: When the primary growth of cancer expands, and a second site within the 
patient develops the cancer.  
 
Melanocytes: A class of cells found in the epidermis (skin).  
 
  
 
 
27 
 
Melanoma: Refers to skin cancer that develops in Melanocytes.  
 
Nucleotides: the building blocks of DNA. They are the individual code pieces. For 
example: the 0s and 1s of computer code.  
 
N-Terminus: The beginning of a protein, as defined by its open amine group (NH2) 
 
Nucleus: The compartment within a cell that houses DNA.  
 
ON-bipolar cells: A class of cell types found in the retina (eye).  
 
Permeability: The ability of a molecule to pass through a membrane. A high 
permeability refers to easy access.  
 
Plasmid: A section of DNA that can be replicated independently and separately from 
the chromosomal DNA. Usually found in bacteria. Usually small and only contain a few 
genes in them.  
 
Polypeptide: This is a chain of amino acids. It folds in on itself, depending on the 
properties of the side chains that make up its amino acids. This folded mass can either 
be autonomous, or may link up with another folded polypeptide to form a fully formed 
protein.  
 
Protein: The little highly specialized ‘machines’ that carry out most functions within 
the body. RNA is translated into a protein.    
 
Proto-oncogenes: These are genes that code for processes that already help the cell 
divide and grow. When mutated, it is possible that they become more potent, and lead to 
more growth/division than normal. 
 
Restriction enzyme: Cuts DNA at a certain site along the nucleotide sequence, 
depending on which enzyme it is. There are varying levels of specificity.  
 
Serum: Refers to the parts of the blood that are not red or white blood cells, clotting 
factors, or fibrinogens. This essentially refers to most proteins, electrolytes, antibodies, 
antigens, and hormones. We mostly cared about the antibodies present.  
 
Substrate: Refers to a molecule that acts as an input in a biological reaction.   
 
Transcription: In biology, this term is used to describe how DNA is converted into 
RNA.  
 
Transfection: Introducing nucleotides into Eukaryotic cells via non-viral methods. 
 
Translation: In biology, this term is used to describe how RNA is converted into 
protein.  
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TRPM1: Transient receptor potential melastatin 1, essentially it is an ion-gated protein 
channel found in melanocytes and ON-bipolar cells. 
 
Tumor suppressor genes: These are genes that code for processes that generally keep 
growth in check, proof-reads DNA sequences, or signals cell death in times of 
emergency. When these genes are rendered useless through certain mutations, it 
becomes easier for cells to grow out of control.  
 
Vasculature: Refers to the organization and distribution of blood vessels throughout 
the body.  
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